{"id":"buprenorphine-transdermal-delivery-system","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Application site reactions (erythema, pruritus)"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-15","effect":"Constipation"},{"rate":"5-10","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor provides a ceiling effect on respiratory depression, making it safer than full opioid agonists. The transdermal delivery system provides sustained, controlled release of the drug through the skin, enabling prolonged therapeutic effect with reduced dosing frequency compared to oral or sublingual formulations.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to produce analgesia and reduce opioid cravings.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:27.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain"},{"name":"Opioid use disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT01999114","phase":"PHASE1","title":"The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2012-03","conditions":"ECG Effects","enrollment":328},{"nctId":"NCT02431624","phase":"PHASE1","title":"An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2015-03","conditions":"Pain","enrollment":40},{"nctId":"NCT02160067","phase":"PHASE1","title":"A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-05","conditions":"Pain","enrollment":20},{"nctId":"NCT00315874","phase":"PHASE3","title":"The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1997-04","conditions":"Back Pain","enrollment":225},{"nctId":"NCT01151098","phase":"PHASE3","title":"Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2001-04","conditions":"Chronic Nonmalignant Pain","enrollment":189},{"nctId":"NCT01148537","phase":"PHASE1","title":"The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2004-07","conditions":"Healthy Volunteers","enrollment":132},{"nctId":"NCT00313846","phase":"PHASE3","title":"Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2003-04","conditions":"Osteoarthritis","enrollment":529},{"nctId":"NCT00324038","phase":"PHASE4","title":"Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2006-03","conditions":"Osteoarthritis","enrollment":219},{"nctId":"NCT00313833","phase":"PHASE3","title":"Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2000-12","conditions":"Chronic Pain","enrollment":100},{"nctId":"NCT00315848","phase":"PHASE3","title":"The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1996-11","conditions":"Osteoarthritis","enrollment":225},{"nctId":"NCT00314652","phase":"PHASE3","title":"Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1999-06","conditions":"Osteoarthritis","enrollment":260},{"nctId":"NCT00315887","phase":"PHASE3","title":"The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1999-04","conditions":"Chronic Low Back Pain","enrollment":250},{"nctId":"NCT00315835","phase":"PHASE2","title":"Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1996-10","conditions":"Postoperative Pain","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Buprenorphine transdermal delivery system","genericName":"Buprenorphine transdermal delivery system","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to produce analgesia and reduce opioid cravings. Used for Moderate to severe chronic pain, Opioid use disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}